Illumina inks a long-term NGS deal with Dutch company Qiagen
Category: #health  By Pankaj Singh  Date: 2019-10-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Illumina inks a long-term NGS deal with Dutch company Qiagen

The pharmaceutical industry is responsible for treating some of the most critical health issues. The sector produces, develops and markets drugs that could be beneficial to people on a larger scale. However, with growing competition in this profitable industry, pharma companies are now planning ahead with ways to expand their market presence.

One such advancement was made recently by Illumina, Inc. who signed a long-term diagnostics partnership with Qiagen, a Dutch pharmaceutical research company that chose to develop kits for Illumina's hardware, instead of developing its own instruments.

As per the agreement, the two firms intend to collaborate on a series of NGS (next-generation sequencing) based tests in various therapeutic regions within the next 15 years. Reportedly, the move comes along the heels of the latest developments in Qiagen, where the company witnessed Peer Schatz, stepping down as the CEO and Chairman, while the firm missed its third-quarter revenue targets.

Reliable reports cite that the Dutch company has planned to reallocate and reprioritize so that it can free some of its resources, which would help it to better focus on its latest venture, such as holding its in-house work on building NGS-related hardware. However, the company assures that it will maintain its support for GeneReader next-gen system’s customers.

Speaking on the move, Peer Schatz said that the collaboration marks as a landmark strategy for the company and will considerably help progress the use of NGS technologies for making a precise clinical decision.

Illumina, on the other hand, has also made some significant development in the Chinese market, when it obtained its first official clearance from the Chinese government for its next-gen, sequencing systems, enabling the firm to commercialize its MiSeqDx device in various institutions and hospitals for in vitro diagnostic testing in the country.

According to Garret Hampton, Executive VP of Clinical Genomics, Illumina, the approval for selling MiSeqDx in China marks as an important cornerstone for the company as it offers more opportunities for NGS.

Source Credit: https://www.fiercebiotech.com/medtech/illumina-qiagen-ink-15-year-companion-diagnostic-partnership-starting-cancer

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Acadia announces positive results of Phase 3 trial to treat psychosis
Acadia announces positive results of Phase 3 trial to treat psychosis
By Pankaj Singh

Acadia Pharmaceuticals, a renowned US-based biopharmaceutical company dedicated to the development of treatments for central nervous system disorders, reportedly announced positive outcomes from its Phase 3 HARMONY stu...

Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.
Senseonics’ Eversense® obtains non-adjunctive labeling claim in U.S.
By Pankaj Singh

Senseonics Holdings, Inc., a US-based medical device startup company recently announced that users of its Eversense CGM (continuous glucose monitoring) system can now use the new Eversense CGM mobile application f...

Astellas Pharma inks a $3 Bln deal to acquire Audentes Therapeutics
Astellas Pharma inks a $3 Bln deal to acquire Audentes Therapeutics
By Pankaj Singh

Japanese pharmaceutical company, Astellas Pharma Inc. has reportedly entered into a definitive agreement to acquire biotech firm Audentes Therapeutics, Inc. at a price of US$60.00 per share in cash, representing equity...